In the realm of mental health treatment, Loncom Pharma’s Vortioxetine Hydrobromide APIs stand out for their multifaceted approach to tackling major depressive disorder. These APIs offer a unique mechanism of action, modulating a range of serotonin receptors and the reuptake process, which contributes to their therapeutic efficacy and a favorable side effect profile, making them a valuable asset for pharmaceutical companies developing next-generation antidepressants.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
